Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Impel NeuroPharma wins FDA approval for migraine nasal spray

The nasal spray uses proprietary delivery technology.

By Brian Buntz | September 3, 2021

Impel Neuropharma

(PRNewsfoto/Impel NeuroPharma)

Impel NeuroPharma (NSDQ:IMPL), a biopharma founded in 2008, has won FDA approval for Trudhesa (dihydroergotamine mesylate) nasal spray as an acute migraine therapy.

The Seattle-based company intends to launch the drug, formerly known as INP104, in early October 2021.

Impel plans to price the drug between $600 and $850 for a package with four doses.

The company will make the drug available via a pharmacy partnership and copay program.

Impel NeuroPharma is using proprietary technology that it has dubbed Precision Olfactory Delivery (POD). The delivery method supports the delivery of dihydroergotamine (DHE) mesylate to the upper nasal cavity, according to the press release.

“The approval of Trudhesa marks the culmination of more than a decade of research and advanced engineering to pair the proven efficacy of DHE with our innovative POD technology,” said Adrian Adams, Impel NeuroPharma CEO, in a statement.

The indication covers migraines with and without aura.

The FDA approval was based on data from the Phase 3, open-label STOP 301 clinical trial, which Impel NeuroPharma bills as “the largest longitudinal study ever conducted with DHE using nasal spray delivery.”

Bausch Health currently has a nasal formulation of dihydroergotamine mesylate on the market known as Migranal but offers a less effective delivery method than Trudhesa, according to Reuters.

Impel NeuroPharma went public via an IPO in April.


Filed Under: clinical trials, Drug Discovery, Neurological Disease
Tagged With: DHE, dihydroergotamine mesylate, Impel NeuroPharma, migraine, Precision Olfactory Delivery, Trudhesa
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50